PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

Lung cancer is the most common cancer in the world, with 2.2 million new cases and around 1.8 million deaths in 2020 alone
News | Lung Imaging
Lung Cancer: When Radiotherapy Fails

July 6, 2022 — Lung cancer is the most common cancer in the world, with 2.2 million new cases and around 1.8 million ...

Time July 06, 2022
arrow
Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed at advancing personalized medicine and improving access to high quality, cost-effective healthcare.
News | Radiology Business
Siemens Healthineers and The Ohio State University Wexner Medical Center Announce Strategic Partnership Focused on Personalized Medicine

June 29, 2022 — Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed ...

Time June 29, 2022
arrow
Andrei Iagaru, MD, FACNM, Receives Inaugural SNMMI Sam Gambhir Trailblazer Award. Courtesy of SNMMI.
News | SNMMI
Andrei Iagaru, MD, FACNM, Receives Inaugural SNMMI Sam Gambhir Trailblazer Award

June 22, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear ...

Time June 22, 2022
arrow
Markus Schwaiger, MD, receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award
News | PET Imaging
Markus Schwaiger, MD, receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

June 21, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as ...

Time June 21, 2022
arrow
Representative case with acute anterior wall myocardial infarction: Myocardial perfusion images using 99mTc-tetrofosmin at rest (first row), 68Ga-FAPI-46 PET (second row), late gadolinium enhancement (LGE) from cardiac magnetic resonance (third row) and schematic drawings of the left ventricle (fourth row). Area of fibroblast activation exceeds infarct area and LGE signal, most common type of myocardial FAP-distribution. Bottom left: Mean areas of perfusion defect, FAPI-signal and LGE of 35 studied patients
News | PET Imaging
SNMMI Image of the Year: New Biomarker Predicts Severity of Cardiac Remodeling After Heart Attack

June 15, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, 68Ga-FAPI ...

Time June 15, 2022
arrow
Cardiac positron emission tomography (PET) perfusion images for two representative patients. Both patients had similar demographic characteristics. Neither patient had significant perfusion abnormalities as shown in the figure. Patient A had mild sleep apnea while patient B had severe obstructive sleep apnea. The corrected myocardial flow reserve (MFR) for patient A was normal at 3.24 while for patient B it was severely abnormal at 1.22.
News | PET Imaging
PET Imaging Confirms Link Between Obstructive Sleep Apnea and Heart Blood Flow Impairment

June 15, 2022 — Patients with severe obstructive sleep apnea (OSA) are less able to increase blood flow to the heart ...

Time June 15, 2022
arrow
Heat maps of PSMA PET prostatic fossa recurrence in patients with recurrence limited to the prostate fossa (miTr N0 M0, n=127), pelvic nodal disease (miTr N1 M0, n=30), distant organs/extra-pelvic nodal disease (miTr N0 M1, n=32) and pelvic nodal plus distant organs/extra-pelvic nodal disease (miTr N1 M1, n=37). The yellow contour represents the RTOG CTV
News | Prostate Cancer
PSMA PET Highlights Need for Updated Prostate Cancer Therapy Guidelines

June 15, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of ...

Time June 15, 2022
arrow
Representative axial image from a test set imaging study. From top left to bottom right: CT (A), NAC-PET (B), original AC-PET (C), AI-generated AC-PET (D). The blue arrow indicates one lesion that was observed in both images, and the red arrow indicates a lesion that was missed (i.e., not de-tected by expert nuclear medicine physicians) in AI image. NAC = Non-Attenuation Corrected. AC = Attenuation-Corrected
News | PET-CT
Virtual CT Scans Cut Patient Radiation Exposure in Half During PET/CT Studies

June 14, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and ...

Time June 14, 2022
arrow
At the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2022 Annual Meeting, GE Healthcare showcases cutting-edge solutions spanning the care continuum and enabling theranostics in prostate cancer
News | Prostate Cancer
GE Healthcare’s Total Molecular Imaging Solutions Enable Precision Health and Theranostics for Personalized Prostate Cancer Care

June 10, 2022 — GE Healthcare provides cutting-edge molecular imaging solutions that enable and increase access to ...

Time June 10, 2022
arrow
Mobile radiology represents a transforming concept that is evolving rapidly in line with notable advancements in the point-of-care (POC) testing arena.
Feature | Digital Radiography (DR) | By ResearchAndMarkets
Global Mobile Imaging Services Market Trajectory and Analytics Report

The "Mobile Imaging Services - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's ...

Time June 09, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

June 8, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 08, 2022
arrow
The global nuclear medicine market size is expected to reach $24.4 billion by 2030, expanding at a CAGR of 13.0% from 2022 to 2030.
Feature | Nuclear Imaging
Global Nuclear Medicine Market Analysis Report

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware of the current global shortage of iodinated contrast media.
News | Contrast Media
Statement from the ACR Committee on Drugs and Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
BioSpec Maxwell preclinical MRI system (Photo: Business Wire)
News | Magnetic Resonance Imaging (MRI)
Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets

May 10, 2022 — At the ISMRM 2022 conference, Bruker announced the launch of innovative 7 Tesla and 9.4 Tesla conduction ...

Time May 10, 2022
arrow
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, announced the enrollment of the first patient into its PREMIER registry, a prospective, real-world evidence clinical outcomes registry for patients with all stages of cancer, at the University of Texas (UT) Southwestern in Dallas.
News | Radiation Therapy
RefleXion Announces Real-World Evidence Outcomes Registry to Evaluate Treatment Impact on all Stages of Cancer

May 4, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) ...

Time May 04, 2022
arrow
Prof. Dr. Samer Ezziddin, image courtesy of Thorsten Mohr/Saarland University
News | Prostate Cancer
New Radiotracer Yields Huge Increase in Accuracy of Localizing Prostate Cancer relapses

April 15, 2022 — Prostate cancer is the most common malignant tumor in men in Germany, with about 62,000 new cases ...

Time April 14, 2022
arrow
Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.
News | PET-CT
New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

Time April 11, 2022
arrow
The Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease.
News | PET Imaging
CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

April 8, 2022 — The Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab ...

Time April 08, 2022
arrow
GE Healthcare announced the first patient dosed in the Phase III clinical trial for a Positron Emission Tomography (PET) radiopharmaceutical imaging agent which aims to assist in the evaluation of adult patients with suspected Parkinsonian syndromes, support research and improve patient care. 
News | PET Imaging
GE Healthcare Announces First Patient Dosed in Phase III Clinical Trial for New Dopamine Transporter Imaging Radiopharmaceutical

March 29, 2022 — GE Healthcare announced the first patient dosed in the Phase III clinical trial for a Positron Emission ...

Time March 29, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now